Processa Pharmaceuticals, INC Schedule 13G passive stakes

CVI Investments, Inc. and Heights Capital Management, Inc. report a combined 7.0% beneficial ownership of Processa Pharmaceuticals, Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 8.1% of Processa Pharmaceuticals, Inc. common stock.

CVI Investments and Heights Capital Management report a 9.0% beneficial ownership stake in Processa Pharmaceuticals, primarily through warrants.

Armistice Capital and Steven Boyd have reduced their beneficial ownership in Processa Pharmaceuticals, Inc. to 4.99% of common stock.

CVI Investments, managed by Heights Capital Management, has reported a 9.9% beneficial ownership stake in Processa Pharmaceuticals, Inc. through warrants.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Processa Pharmaceuticals, Inc. through a warrant.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 9.9% beneficial ownership stake in Processa Pharmaceuticals, Inc., totaling 2,663,078 shares.

3i, LP, along with its affiliates, has filed a Schedule 13G indicating a reduction in its beneficial ownership of Processa Pharmaceuticals, Inc. common stock to 4.9% following a recent public offering and subsequent dispositions, marking this as an exit filing.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 9.99% in Processa Pharmaceuticals, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Processa Pharmaceuticals, Inc. as of March 31, 2025, held for investment purposes in the ordinary course of business.